Haleon PLC

Transaction in Own Shares • Sep 23, 2025

National Storage Mechanism | Additional information

RNS Number : 3321A

Haleon PLC

23 September 2025

Haleon plc: Transaction in own shares

23 September 2025: Haleon plc (the "Company" or "Haleon") today announces the purchase of 5,150,000 ordinary shares of £0.01 each in the Company (the "Shares") under the second tranche of its share buyback programme announced on 31 July 2025.

	London Stock Exchange	CBOE (UK)/BXE	CBOE (UK)/CXE
Date of purchase:	22 September 2025	22 September 2025	22 September 2025
Number of Shares purchased:	3,507,000	1,000,000	643,000
Highest price paid per Share (p):	336.6000	334.0000	336.4000
Lowest price paid per Share (p):	332.7000	332.6000	332.7000
Volume weighted average price paid per Share (p):	333.9574	333.6379	333.9485

The Company intends to hold the purchased shares as treasury shares.

Following the settlement of the above, the Company's registered share capital is 8,952,353,648 ordinary shares of  £0.01 each, of which 28,187,545 are held as treasury shares. Therefore, the number of ordinary shares with voting rights is 8,924,166,103 and this figure may be used by shareholders to determine if they are required to notify their interest, or a change to their interest, in Haleon under the FCA's Disclosure Guidance and Transparency Rules.

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 as it applies in the UK (the Market Abuse Regulation), a full breakdown of the individual trades is available at the link below:

http://www.rns-pdf.londonstockexchange.com/rns/3321A_1-2025-9-22.pdf

This announcement does not constitute, or form part of, an offer or any solicitation of an offer for securities in any jurisdiction.

This announcement and individual trade breakdown will also be available on the Company's website at: www.haleon.com/investors .

Enquiries
Investors		Media
Jo Russell	+ 44 7787 392441	Zo ë Bird	+44 7736 746167
Rakesh Patel	+44 7552 484646	Victoria Durman	+44 7894 505730
Email: [email protected]		Email: [email protected]

About Haleon

Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.

For more information, please visit   www.haleon.com . 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

POSVLLFLEKLLBBQ